Литература
1. Byrne C.D., Targher G. NAFLD: a multisystem disease // J. Hepatol. 2015. Vol. 62. Suppl. 1. P. S. 47–64.
2. Sayiner M., Koenig A., Henry L., Younossi Z.M. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20:205–214.
3. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006 Feb; 43 (2 Suppl 1):S. 99-S11.
4. Koenig A.B. et al. Hepathology. 2015; 62(1 Suppl): 1286A.
5. Ивашкин B.T., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2, РЖГГК, 2015, 6, 31–41.
6. Диагностика и лечение неалкогольной жировой болезни печени. Под ред. академика РАН, проф. Ивашкина В.Т. — Методические рекомендации для врачей. — Российское общество по изучению печени. — М., 2015.
7. Bhatia L.S. et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? European Heart Journal. 2012. 33:1190–1200. / doi:10.1093/eurheartj/ehr453.
8. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, (2012). 55: 2005–2023.
9. Harrison’s Principles of Internal Medicine, 17th ed., New York: McGraw-Hill Medical Publishing Division.
10. Шерлок ILL, Дули Дж. Заболевания печени и желчных путей: практическое руководство / Пер. с англ. / Под ред. Апросиной З.Г., Мухина Н.А. — М.: Гэотар Медицина, 1999. — 864 с.
11. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update // Obesity Reviews. — 2010. — № 11(6). — P. 430–45.
12. McPherson S., Hardy T., Henderson E. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management //J. Hepatol. 2015. Vol. 62. № 5. P. 1148–1155.
13. Musso G., Gambino R., Cassader M., Pagano G.F., (2011). Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617–649.
14. Benedict M., Zhang X.. Non-alcoholic fatty liver disease: An expanded review. World Journal of Hepatology. 2017;9(16):715–732. doi:10.4254/wjh.v9.il6.715.
15. Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective // Semin Liver Dis. -2008.-№ 28(4). — P. 339–50.
16. Doycheva, Cui J., Nguyen P. et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Alimentary Pharmacology & Therapeutics, January 2016, Volume 43, Issue 1, pages 83–95.
17. Lonardo A., Bellentani S., Argo C.K. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015; 47(12):997-1006. doi: 10.1016/j.dld.2015.08.004.
18. Ballestri S.,Nascimbeni F., Baldelli E. et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv. Ther. 2017; 34(6): 1291–1326. Published online 2017 May 19. doi: 10.1007/S12325-017-0556-1.
19. Sookoian S., Pirola C.J. Genetic predisposition in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2017;23(1):1-12. doi:10.3350/cmh.2016.0109.
20. Caligiuri A., Gentilini A., Marra F. Molecular Pathogenesis of NASH. International Journal of Molecular Sciences. 2016;17(9):1575. doi:10.3390/ijmsl7091575.
21. Green C J., Hodson L. The Influence of Dietary Fat on Liver Fat Accumulation. Nutrients. 2014;6(ll):5018–5033. doi:10.3390/nu6115018.
22. Ferramosca A., Zara V. Modulation of hepatic steatosis by dietary fatty acids. World Journal of Gastroenterology: WJG. 2014;20(7):1746–1755. doi:10.3748/wjg.v20.i7.1746.
23. Chakraborty S. Analysis of NHANES 1999–2002 data reveals noteworthy association of alcohol consumption with obesity. Ann Gastroenterol. 2014;27(3):250-257
24. Zakhari S., Li T.K. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology, 2007;46:2032–2039.
25. Rutkowski J.M., Stern J.H., Scherer P.E. The cell biology of fat expansion. J Cell Biol Mar 2015,208 (5) 501–512; DOI: 10.1083/jcb.201409063.
26. Schaffer J.E. Lipotoxicity: Many Roads to Cell Dysfunction and Cell Death: Introduction to a Thematic Review Series. Journal of Lipid Research. 2016;57(8):1327–1328. doi:10.1194/jlr.E069880.
27. Byrne C.D. Dorothy Hodgkin Lecture 2012: nonalcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 29(9):1098-107.
28. Tsochatzis E.A. Adipokines in Nonalcoholic Steato-hepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. Mediators Inflamm. 2009: 831670.
29. Lonardo A., Sookoian S., Chonchol M.et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease — atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013;19(29):5177-92.
30. Wende A.R., Symons J.D., Abel E.D. Mechanisms of Lipotoxicity in the Cardiovascular System. Current hypertension reports. 2012;14(6):517–531. doi:10.1007/sll906-012-0307.
31. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 Apr;37(4):917-23.
32. Min H.K. et al. Increased hepatic synthesis and dysr?gulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012 May 2;15(5):665-74.
33. Brown M.S., Goldstein J.L. Nobel lecture, 9 December, 1985.
34. Fuchs M. et al. Gastroenterology, 2012; Vol. 142, Issue 5, S-1015.
35. Musso G., Gambino R., Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013 Jan;52(l):175-91. doi: 10.1016/j. plipres.2012.11.002. Epub 2012 Dec 1.
36. Вовк Е.И. Неалкогольная жировая болезнь печени: от научных достижений к клиническим алгоритмам. Медицинский совет; 2013; № 10; http://dx.doi. org/10.21518/2079-701X-2013-10-46-51.
37. Targher G., Day C.P., Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl J Med 2010; 363:1341–1350 DOI: 10.1056/NEJMra0912063.
38. Oni E.T. et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013;230:258–267.
39. Драпкина O.M., Чапаркина С.О. Взаимосвязь метаболического синдрома, асептического воспаления и дисфункции эндотелия // Российские медицинские вести. 2007. Т. 12. № 3. С. 67–75.
40. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008;49(4):600-7.
41. Fracanzani A.L., Pisano G., Consonni D., et al. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. Targher G, ed. PLoS ONE. 2016;ll(9):e0162473. doi:10.1371/journal.pone.0162473.
42. Sookoian S. et al. Cardiovascular phenotype of nonalcoholic fatty liver disease: Hanging the paradigm about the role of distant toxic fat accumulation on vascular disease. Hepatology, 2012; 56(3):1185-86.
43. Targher G., Valbusa F., Bonapace S., et al. Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes. Manco M, ed. PLoS ONE. 2013;8(2):e57183. doi:10.1371/ journal.pone.0057183
44. Ballestri S., Lonardo A., Bonapace S. et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology: WJG. 2014;20(7):1724–1745. doi:10.3748/ wjg.v20.i7.1724.
45. Lonardo A., Targher G., eds. International Journal of Molecular Sciences. 2016;17(4):562.
46. Ix J.H., Sharma K. Mechanisms Linking Obesity, Chronic Kidney Disease, and Fatty Liver Disease: The Roles of Fetuin-A, Adiponectin, and AMPK. Journal of the American Society of Nephrology: JASN. 2010;21(3):406–412. doi:10.1681/ASN.2009080820.
47. Musso G., Gambino R., Tabibian J.H., et al. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. Woodward M, ed. PLoS Medicine. 2014;ll(7):el001680. doi:10.1371/ journal.pmed.1001680.
48. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J Hepatol. 2016. Vol. 64 (6). P. 1388–1402.
49. Chalasani N. Who should be screened for NASH? // Ann N Y Acad Sei. — 2013. — Vol. 1281. — P. 106–22.
50. Hart C., Morrison D., Batty G., et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010; 340:1240.
51. Liu B. et al. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010; 340:912.
52. World Gastroenterology Organisation Global Guidelines Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, June 2012; www.who.org.
53. Yasutake K., Kohjima M., Kotoh K., et al. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World Journal of Gastroenterology: WJG. 2014;20(7):1756–1767. doi:10.3748/wjg.v20.i7.1756.
54. Ferolla S.M., Silva L.C., Ferrari M. de LA, et al. Dietary approach in the treatment of nonalcoholic fatty liver disease. World Journal of Hepatology. 2015;7(24):2522–2534. doi:10.4254/wjh.v7.i24.2522.
55. Zelber-Sagi S., Ratziu V., Oren R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World Journal of Gastroenterology: WJG. 2011;17(29):3377–3389. doi:10.3748/wjg.vl7.i29.3377.
56. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis (NASH). Hepatology (Baltimore, Md). 2010;51(1):121–129. doi:10.1002/hep. 23276.
57. Loria P., Adinolfi L.E., Bellentani S. et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee.Dig Liver Dis. 2010 Apr; 42(4):272-82.
58. Castro-Quezada L, S?nchez-Villegas A., Estruch R., et al. A High Dietary Glyc?mie Index Increases Total Mortality in a Mediterranean Population at High Cardiovascular Risk. Gorlova OY, ed. PLoS ONE. 2014;9(9):el07968. doi:10.1371/ journal.pone.0107968.
59. Zelber-Sagi S., Godos J., Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therapeutic Advances in Gastroenterology. 2016;9(3):392–407. doi:10.1177/ 1756283X16638830.
60. Jesch E.D., Carr T.P. Food Ingredients That Inhibit Cholesterol Absorption. Preventive Nutrition and Food Science. 2017;22(2):67–80. doi:10.3746/pnf.2017.22.2.67.
61. Lefebvre P., Cariou B., Lien F. et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009 Jan;89(l):147-91. doi: 10.1152/physrev.00010.2008.
62. Watanabe M., Houten S.M., Mataki C. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006 Jan 26;439(7075):484-9.
63. Willett W.C., Sacks F., Trichopoulou A.,et al. Mediterranean diet pyramid: a cultural model for healthy eating // Am J Clin Nutr. 1995 Jun;61(6 Suppl):1402S-1406S.
64. WHO/FAO (2003) Diet nutrition and the prevention of chronic diseases. Geneva, Switzerland. Available at www.who.int.
65. Hu F.B., Willett W.C. (2002) Optimal diets for prevention of coronary heart disease. JAMA. 2002 Nov 27; 288(20):2569-78. Review.
66. Estruch R., Ros E., Salas-Salvad? J. et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4; 368(14):1279-90.
67. Gunge V.B., Andersen I., Куш C., et al. Adherence to a healthy Nordic food index and risk of myocardial infarction in middle-aged Danes: the diet, cancer and health cohort study. Eur J Clin Nutr. 2017 May;71(5):652–658. doi: 10.1038/ ejcn.2017.1. Epub 2017 Mar 1.
68. Sofi F., Casini A. Mediterranean diet and nonalcoholic fatty liver disease: New therapeutic option around the corner? World Journal of Gastroenterology: WJG. 2014;20 (23):7339–7346. doi:10.3748/wjg.v20.i23.7339.
69. Eckard C., Cole R., Lockwood J., et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic Advances in Gastroenterology. 2013;6(4):249–259. doi:10.1177/ 1756283X13484078.
70. Tzima N., Pitsavos C., Panagiotakos D.B. et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. Nutr Metab (bond). 2009 Jul 30; 6():30.
71. Martinez-Gonzalez M.A., de la Fuente-Arrillaga C., Nunez-Cordoba J.M. et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ. 2008 Jun 14; 336(7657):1348-51.
72. Ryan M.C., Itsiopoulos C., Thodis T. et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013 Jul;59(l):138-43. doi: 10.1016/j. jhep.2013.02.012. Epub 2013 Feb 26.
73. TuomilehtoJ., Lindstr?m J., Eriksson J., et al., for the Finnish Diabetes Prevention Study Group. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med 2001; 344:1343–1350. DOI: 10.1056/NEJM200105033441801.
74. Nadtochiy S.M., Redman E.K. Mediterranean diet and cardioprotection: the role of nitrite, polyunsaturated fatty acids and polyphenols. Nutrition (Burbank, Los Angeles County, Calif). 2011;27(7–8):733–744. doi:10.1016/j.nut.2010.12.006.
75. Simopoulos A.P. Human requirement for Q-3 polyunsaturated fatty acids. Poult Sei. 2000 Jul; 79(7):961-70.
76. Weber P.C., Leaf A. Cardiovascular effects of omega-3 fatty acids. Atherosclerosis risk factor modification, 1991.
77. Rodriguez-Leyva D., et al. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol. 2010 November; 26(9): 489–496.
78. Leyva D.R., Zahradka P., Ramjiawan B., et al. The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled trial. Contemp Clin Trials. 2011; 32: 724–730.
79. Parker H.M., Johnson N.A., Burdon C.A., et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012 Apr;56(4):944-51. doi: 10.1016/j.jhep.2011.08.018.
80. Sonne D.P., Knop F.K. Cardiovascular effects of alpha-linolenic acid-a possible role of glucagon-like peptide-1. Exp Biol Med (Maywood). 2013 Oct;238(10):1116-7. doi: 10.1177/1535370213503434.
81. Gundermann K.-J., Gundermann S., Drozdzik M., Mohan Prasad V. Essential phospholipids in fatty liver: a scientific update. Clinical and Experimental Gastroenterology. 2016;9:105–117. doi:10.2147/CEG.S96362.
82. Kidd P.M. Cell membranes, endothelia, and atherosclerosis — the importance of Phosphatidylcholine. Altern Med Rev 1996;1:148–167.
83. Un C., Zheng X., Tan Z. et al. Clinical Observation on Polyene Phosphatidyl Choline and Metformin in the Treatment of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease // Clin Focus. — 2008. — Vol. 23, N 17. — P. 1272–3.
84. Yin Kong. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus // Med J Qilu. — 2000. — Vol. 15. — P. 277–8.
85. Guo S. Observation on treatment of fatty liver disease with polyene phosphatidylcholine // China Foreign Med J. 2007. Vol. 5, Issue 10.
86. Kuntz E., Kuntz H.-D. Гепатология: учебное пособие и атлас. 3-е изд. — Springer Press, Heidelberg 2008; глава 40., С. 896.
87. Sas et al. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis Journal of Hepatology 2013; 58: S549 (EASL congress 2013) & Hepatol Int (2013) 7 (Suppl 1):S71.
88. Singal A.K., Jampana S.C., Weinman S.A. Liver Int. 2011; 31(10): 1432–1448.
89. OkiyamaW. et al. J Hepatol. 2009 Jun; 50(6): 1236–1246.
90. MazzellaN., Ricciardi L.M., Mazzotti A., Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis. 2014 Feb;18(l):73–89. doi: 10.1016/j. cld.2013.09.005.
91. Hallsworth K., Avery L., Trenell M.I. Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature. Curr Gastroenterol Rep. 2016 Mar;18(3):ll. doi: 10.1007/S11894-016-0485-1.
